295 related articles for article (PubMed ID: 34989830)
1. The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.
Fugger G; Bartova L; Fabbri C; Fanelli G; Dold M; Swoboda MMM; Kautzky A; Zohar J; Souery D; Mendlewicz J; Montgomery S; Rujescu D; Serretti A; Kasper S
Eur Arch Psychiatry Clin Neurosci; 2022 Jun; 272(4):715-727. PubMed ID: 34989830
[TBL] [Abstract][Full Text] [Related]
2. Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder.
Bartova L; Fugger G; Dold M; Kautzky A; Fanelli G; Zanardi R; Albani D; Weidenauer A; Rujescu D; Souery D; Mendlewicz J; Montgomery S; Zohar J; Fabbri C; Serretti A; Kasper S
J Affect Disord; 2023 Jul; 332():105-114. PubMed ID: 36958488
[TBL] [Abstract][Full Text] [Related]
3. Melancholic features in major depression - a European multicenter study.
Dold M; Bartova L; Fugger G; Kautzky A; Mitschek MMM; Fabbri C; Montgomery S; Zohar J; Souery D; Mendlewicz J; Serretti A; Kasper S
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110285. PubMed ID: 33609603
[TBL] [Abstract][Full Text] [Related]
4. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder.
Fugger G; Bartova L; Dold M; Fabbri C; Fanelli G; Zanardi R; Kautzky A; Zohar J; Souery D; Mendlewicz J; Montgomery S; Rujescu D; Serretti A; Kasper S
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 114():110480. PubMed ID: 34826558
[TBL] [Abstract][Full Text] [Related]
5. The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.
Bartova L; Fugger G; Dold M; Kautzky A; Swoboda MMM; Rujescu D; Zohar J; Souery D; Mendlewicz J; Montgomery S; Fabbri C; Serretti A; Kasper S
Int J Neuropsychopharmacol; 2022 Feb; 25(2):118-127. PubMed ID: 34637516
[TBL] [Abstract][Full Text] [Related]
6. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
7. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
[TBL] [Abstract][Full Text] [Related]
8. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
9. Agomelatine versus other antidepressive agents for major depression.
Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
Cochrane Database Syst Rev; 2013 Dec; (12):CD008851. PubMed ID: 24343836
[TBL] [Abstract][Full Text] [Related]
10. Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study.
Dold M; Bartova L; Kautzky A; Serretti A; Porcelli S; Souery D; Mendlewicz J; Montgomery S; Zohar J; Kasper S
Eur Neuropsychopharmacol; 2018 Dec; 28(12):1305-1313. PubMed ID: 30446357
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study.
Dold M; Kautzky A; Bartova L; Rabl U; Souery D; Mendlewicz J; Porcelli S; Serretti A; Zohar J; Montgomery S; Kasper S
Eur Neuropsychopharmacol; 2016 Dec; 26(12):1960-1971. PubMed ID: 27816317
[TBL] [Abstract][Full Text] [Related]
12. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
[TBL] [Abstract][Full Text] [Related]
13. Vortioxetine: a New Treatment for Major Depressive Disorder.
Connolly KR; Thase ME
Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
[TBL] [Abstract][Full Text] [Related]
14. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD).
Keyloun KR; Hansen RN; Hepp Z; Gillard P; Thase ME; Devine EB
CNS Drugs; 2017 May; 31(5):421-432. PubMed ID: 28378157
[TBL] [Abstract][Full Text] [Related]
15. [Use of antidepressant drugs in schizophrenic patients with depression].
Micallef J; Fakra E; Blin O
Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
[TBL] [Abstract][Full Text] [Related]
16. Association analysis of gut microbiota and efficacy of SSRIs antidepressants in patients with major depressive disorder.
Gao M; Tu H; Liu P; Zhang Y; Zhang R; Jing L; Zhang K
J Affect Disord; 2023 Jun; 330():40-47. PubMed ID: 36871910
[TBL] [Abstract][Full Text] [Related]
17. Antidepressants for the treatment of depression in people with cancer.
Ostuzzi G; Matcham F; Dauchy S; Barbui C; Hotopf M
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011006. PubMed ID: 26029972
[TBL] [Abstract][Full Text] [Related]
18. The Korean Medication Algorithm for Depressive Disorder: second revision.
Seok Seo J; Rim Song H; Bin Lee H; Park YM; Hong JW; Kim W; Wang HR; Lim ES; Jeong JH; Jon DI; Joon Min K; Sup Woo Y; Bahk WM
J Affect Disord; 2014; 167():312-21. PubMed ID: 25010375
[TBL] [Abstract][Full Text] [Related]
19. Prediction of early improvement of major depressive disorder to antidepressant medication in adolescents with radiomics analysis after ComBat harmonization based on multiscale structural MRI.
Ma H; Zhang D; Wang Y; Ding Y; Yang J; Li K
BMC Psychiatry; 2023 Jun; 23(1):466. PubMed ID: 37365541
[TBL] [Abstract][Full Text] [Related]
20. [Fluoxetine: an update of its use in major depressive disorder in adults].
Gourion D; Perrin E; Quintin P
Encephale; 2004; 30(4):392-9. PubMed ID: 15597466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
